Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ATAI logo ATAI
Upturn stock ratingUpturn stock rating
ATAI logo

ATAI Life Sciences BV (ATAI)

Upturn stock ratingUpturn stock rating
$2.19
Last Close (24-hour delay)
Profit since last BUY19.02%
upturn advisory
Consider higher Upturn Star rating
BUY since 29 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: ATAI (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

7 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $9

1 Year Target Price $9

Analysts Price Target For last 52 week
$9Target price
Low$1.03
Current$2.19
high$2.64

Analysis of Past Performance

Type Stock
Historic Profit -50.38%
Avg. Invested days 24
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 463.64M USD
Price to earnings Ratio -
1Y Target Price 9
Price to earnings Ratio -
1Y Target Price 9
Volume (30-day avg) 7
Beta 1.48
52 Weeks Range 1.03 - 2.64
Updated Date 06/30/2025
52 Weeks Range 1.03 - 2.64
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.91

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -1239.23%

Management Effectiveness

Return on Assets (TTM) -26.04%
Return on Equity (TTM) -79.43%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 389997994
Price to Sales(TTM) 248.87
Enterprise Value 389997994
Price to Sales(TTM) 248.87
Enterprise Value to Revenue 209.34
Enterprise Value to EBITDA 0.27
Shares Outstanding 210746000
Shares Floating 111215420
Shares Outstanding 210746000
Shares Floating 111215420
Percent Insiders 8.22
Percent Institutions 33.4

Analyst Ratings

Rating 3
Target Price 9
Buy 2
Strong Buy 5
Buy 2
Strong Buy 5
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

ATAI Life Sciences BV

stock logo

Company Overview

overview logo History and Background

ATAI Life Sciences BV was founded in 2018. It focuses on developing psychedelic and non-psychedelic compounds for various mental health disorders. ATAI went public in 2021.

business area logo Core Business Areas

  • Drug Development: ATAI invests in and incubates companies developing novel mental health treatments.
  • Platform Development: ATAI is building a technology platform to improve the efficiency of drug development and patient care in mental health.

leadership logo Leadership and Structure

Florian Brand is the CEO and co-founder. The company has a management team with experience in biotech, pharmaceuticals, and venture capital. They operate a decentralized model, investing in and supporting subsidiary companies.

Top Products and Market Share

overview logo Key Offerings

  • PCN-101 (R-ketamine): Developed by Perception Neuroscience. Targeting Treatment-Resistant Depression. Competitors include Janssen's Spravato (esketamine).
  • RL-007: Developed by Revivo Bio, it modulates glutamatergic neurotransmission. Targeting Cognitive Impairment Associated with Schizophrenia. Competitors: Currently limited as it is a unique approach.
  • VLS-01: Developed by Viridia Life Sciences. Targeting opioid use disorder. Competitors: Methadone and Buprenorphine.

Market Dynamics

industry overview logo Industry Overview

The mental health market is growing due to increasing awareness and unmet needs. Psychedelic-assisted therapies are gaining acceptance.

Positioning

ATAI is a leading player in the psychedelic medicine space, with a diversified portfolio of compounds targeting various mental health conditions. They have a first-mover advantage, but also face regulatory and public perception hurdles.

Total Addressable Market (TAM)

The global mental health market is estimated at hundreds of billions of dollars. ATAI is targeting specific sub-segments like TRD, schizophrenia, and addiction. The TAM for these indications is substantial, positioning ATAI for significant growth potential, if trials are successful.

Upturn SWOT Analysis

Strengths

  • Diversified pipeline
  • Strong financial backing
  • Experienced management team
  • Decentralized operating model
  • First-mover advantage in psychedelic medicine

Weaknesses

  • High cash burn rate
  • Reliance on clinical trial success
  • Regulatory uncertainty
  • Public perception of psychedelics
  • Relatively new company

Opportunities

  • Partnerships with pharmaceutical companies
  • Expansion into new therapeutic areas
  • Positive clinical trial results
  • Regulatory approval of psychedelic therapies
  • Growing acceptance of psychedelic medicine

Threats

  • Clinical trial failures
  • Regulatory setbacks
  • Competition from established pharmaceutical companies
  • Negative publicity surrounding psychedelics
  • Economic downturn affecting investment in biotech

Competitors and Market Share

competitor logo Key Competitors

  • JNJ
  • AVXL
  • GHRS

Competitive Landscape

ATAI's advantage lies in its focus on psychedelic medicine and its diversified pipeline. However, established pharmaceutical companies have greater resources and experience in drug development and commercialization.

Major Acquisitions

Perception Neuroscience

  • Year: 2020
  • Acquisition Price (USD millions): 20.7
  • Strategic Rationale: Acquisition of Perception Neuroscience provided ATAI with access to PCN-101 (R-ketamine), a promising treatment for TRD.

Growth Trajectory and Initiatives

Historical Growth: Growth has been driven by acquisitions of promising compounds and companies in the mental health space.

Future Projections: Analysts project significant revenue growth if ATAI's key compounds receive regulatory approval. However, projections are highly dependent on clinical trial outcomes.

Recent Initiatives: Recent initiatives include advancing clinical trials for PCN-101 and RL-007, and exploring new partnerships and acquisitions.

Summary

ATAI Life Sciences is a promising company in the emerging psychedelic medicine space, with a diversified pipeline and strong financial backing. However, it faces significant risks related to clinical trial outcomes, regulatory uncertainty, and public perception. ATAI needs to manage its cash burn carefully and achieve positive clinical trial results to realize its full potential. Its decentralized model allows for innovative drug development but adds inherent risk in terms of oversight.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings
  • Analyst reports
  • Press releases
  • Market research reports

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. The data is based on publicly available information and is subject to change. Investing in biotech companies is inherently risky.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About ATAI Life Sciences BV

Exchange NASDAQ
Headquaters -
IPO Launch date 2021-06-18
Co-Founder & CEO Dr. Srinivas G. Rao M.D., Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 54
Full time employees 54

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic in Phase 2a trial for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists in preclinical studies for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.